The cell suspension was transferred to the top of a 15 mL tube prepared with four layered densities of Optiprep (Cosmo Bio, Carlsbad, CA, AXS-1114542)
The study design employed was randomized controlled trials (RCTs) Table 1

Disclosures: Maria Stepanova: Nothing to Disclose, Robert Wong: Theratechnologies: Grant/Research Support, Durect: Grant/Research Support, Gilead Sciences: Grant/Research Support, Exact Sciences: Grant/Research Support, Theratechnologies: Grant/Research Support, Durect Corporation: Grant/Research Support, Ashwani Singal: Nothing to Disclose, Veronica Nguyen: Nothing to Disclose, Linda Henry: Nothing to Disclose, Saleh Alqahtani: Nothing to Disclose, Zobair Younossi: Nothing to Disclose 1510 PRIOR DIAGNOSIS OF DECOMPENSATED ALCOHOL-ASSOCIATED LIVER DISEASE DOES NOT INCREASE RISK OF ALCOHOL RELAPSE DURING TRANSPLANT EVALUATION AND MAY INCREASE RISK OF POST-TRANSPLANT ALCOHOL RELAPS Sasha Deutsch-Link 1 Kevin Wang 1 Weiyu Wu 2 Allison Kwong 2 Kawthar Mohamed 3 Nicholas Lim 3 Katherine Cooper 4 Deepika Devuni 4 Anjana Rajan 5 Amanda Cheung 6 Kaleb Tesfai 7 Veeral Ajmera 8 Hersh Shroff 1 , 1 UNC Chapel Hill, 2 Stanford University Medical Center, 3 University of Minnesota, 4 University of Massachusetts, 5 Northwestern Feinberg School of Medicine, 6 Northwestern Memorial Hospital/Northwestern University, 7 University of California San Diego, 8 University of California, San Diego Background: Access to liver transplant (LT) patients with alcohol-associated liver disease (ALD) has expanded in the past decade

As both play very important roles in the immune response, and the status or availability of one has been shown to directly affect the other, it is likely that deficiency of either can have a direct effect on the severity of COVID-19 as well as many other diseases therefore, taking steps to ensure adequate levels of both is essential to better health